« Previous
Next »
The American Journal of Medicine
Volume 119, Issue 8
, Pages e3-e5
, August 2006
Rituximab-induced Elimination of Acquired Angioedema Due to C1-Inhibitor Deficiency
References
- . Hereditary and acquired C1-inhibitor deficiency (biological and clinical characteristics in 235 patients). Medicine (Baltimore). 1992;71:206–215
- . Acquired C1 esterase inhibitor deficiency. Ann Intern Med. 2000;132:144–150
- . An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986;323:722–724
- . Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore). 2003;82:274–281
- . C1-inhibitor deficiency and angioedema. Mol Immunol. 2001;38:161–173
- Acquired angioedema with C1 inhibitor deficiency (is the distinction between type I and type II still relevant?). Dermatology. 1999;199:227–230
- . Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol. 1996;106:475–480
- C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. J Allergy Clin Immunol. 1996;97:998–1008
- Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51–S131
- . Rituximab (monoclonal anti-CD20 antibody) (mechanisms of action and resistance). Oncogene. 2003;22:7359–7368
- . Rituximab therapy and autoimmune disorders (prospects for anti-B cell therapy). Arthritis Rheum. 2003;48:1484–1492
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma (half of patients respond to a four-dose treatment program). J Clin Oncol. 1998;16:2825–2833
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
- . Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford). 2005;44:151–156
- . Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
- B cell depletion as a novel treatment for systemic lupus erythematosus (a phase I/II dose-escalation trial of rituximab). Arthritis Rheum. 2004;50:2580–2589
- Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581
- . Acquired angioedema (a new target for rituximab). Haematologica. 2004;89:ELT13
PII: S0002-9343(05)00860-0
doi: 10.1016/j.amjmed.2005.09.018
© 2006 Elsevier Inc. All rights reserved.
« Previous
Next »
The American Journal of Medicine
Volume 119, Issue 8
, Pages e3-e5
, August 2006

